HC Wainwright Issues Pessimistic Forecast for Arcturus Therapeutics (NASDAQ:ARCT) Stock Price

Arcturus Therapeutics (NASDAQ:ARCT - Free Report) had its price target lowered by HC Wainwright from $63.00 to $60.00 in a report issued on Friday morning, Marketbeat Ratings reports. The firm currently has a buy rating on the biotechnology company's stock.

A number of other equities analysts have also recently issued reports on the company. BTIG Research started coverage on Arcturus Therapeutics in a report on Tuesday, January 28th. They set a "buy" rating and a $41.00 target price for the company. Cantor Fitzgerald reiterated an "overweight" rating on shares of Arcturus Therapeutics in a report on Friday. Finally, Wells Fargo & Company dropped their target price on Arcturus Therapeutics from $58.00 to $50.00 and set an "overweight" rating on the stock in a research report on Friday. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Buy" and an average price target of $59.20.

Arcturus Therapeutics Trading Down 7.6 %

Shares of NASDAQ:ARCT traded down $1.08 during trading on Friday, hitting $13.21. 568,323 shares of the company's stock traded hands, compared to its average volume of 425,942. The company has a 50-day moving average price of $16.83 and a 200-day moving average price of $18.44. Arcturus Therapeutics has a 52 week low of $12.75 and a 52 week high of $45.00. The company has a market cap of $357.82 million, a price-to-earnings ratio of -5.95 and a beta of 2.96.

Remove Ads

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last announced its quarterly earnings results on Thursday, March 6th. The biotechnology company reported ($1.11) earnings per share for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.78). Arcturus Therapeutics had a negative net margin of 36.39% and a negative return on equity of 22.39%. The company had revenue of $22.77 million during the quarter, compared to the consensus estimate of $44.64 million. On average, analysts predict that Arcturus Therapeutics will post -2.22 earnings per share for the current fiscal year.

Institutional Trading of Arcturus Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Virtus ETF Advisers LLC boosted its holdings in shares of Arcturus Therapeutics by 38.8% in the 4th quarter. Virtus ETF Advisers LLC now owns 4,051 shares of the biotechnology company's stock valued at $69,000 after buying an additional 1,132 shares during the last quarter. KLP Kapitalforvaltning AS bought a new position in shares of Arcturus Therapeutics in the 4th quarter valued at about $71,000. National Bank of Canada FI grew its position in shares of Arcturus Therapeutics by 639.6% in the 4th quarter. National Bank of Canada FI now owns 5,532 shares of the biotechnology company's stock valued at $94,000 after acquiring an additional 4,784 shares during the period. Kennedy Capital Management LLC increased its stake in shares of Arcturus Therapeutics by 22.7% during the 4th quarter. Kennedy Capital Management LLC now owns 10,987 shares of the biotechnology company's stock worth $186,000 after purchasing an additional 2,036 shares during the last quarter. Finally, Sherbrooke Park Advisers LLC bought a new stake in shares of Arcturus Therapeutics in the 4th quarter valued at about $200,000. Institutional investors own 94.54% of the company's stock.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.